Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $27.3600 (3.68%) ($26.8200 - $29.1500) on Wed. Feb. 21, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.48% (three month average) | RSI | 26 | Latest Price | $27.3600(3.68%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -4% a day on average for past five trading days. | Weekly Trend | ADMS declines -7.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(25%) IBB(22%) IWM(18%) IWO(18%) QQQ(18%) | Factors Impacting ADMS price | ADMS will decline at least -2.24% in a week (0% probabilities). VIXM(-12%) UNG(-10%) BNDX(-9%) UUP(-8%) TLT(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.24% (StdDev 4.48%) | Hourly BBV | 0 () | Intraday Trend | 2% | | | |
|
1 - 5 Day Possible Target | $12.68(-53.65%) | Resistance Level | $35.57 | 5 Day Moving Average | $31.4(-12.87%) | 10 Day Moving Average | $32.87(-16.76%) | 20 Day Moving Average | $35.57(-23.08%) | To recent high | -35.8% | To recent low | 3.7% | Market Cap | $774m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |